A UCLA-led study estimates that more than 28,000 deaths could be prevented each year in the U.S. through the use of a new class of cardiovascular medication approved by the U.S. Food and Drug Administration. The medication helps reduce mortality in patients diagnosed with heart failure and reduced ejection fraction, the percentage of blood pumped from the heart with each contraction.
Previous studies have demonstrated that angiotensin receptor neprilysin inhibitor (ARNI) therapy using a new class of medication, sacubitril and valsartan, reduces mortality in patients with heart failure and reduced ejection fraction. The therapy works by enhancing the body’s protective hormonal systems while simultaneously inhibiting the overactive hormones that harm the heart.
In this study, researchers wanted to quantify the number of deaths that could be prevented or postponed with ARNI therapy. Researchers conducted the study by analyzing published data of patients who were eligible for the therapy, estimates of the number of people in the U.S. diagnosed with heart failure and reduced ejection fraction and the numbers needed to treat with the medication to avert death.
More than 2.7-million patients in the U.S. have been diagnosed with heart failure and reduced ejection fraction. Of these patients, 84 percent (almost 2.3 million) are potential candidates for ARNI therapy. This study showed that if ARNI therapy were comprehensively applied to eligible patients, it could potentially prevent 28,484 deaths each year.
“These findings support the timely implementation of ARNI therapy into routine clinical practice because this will have a substantial impact on population health for patients with heart failure,” says the study’s lead author, Gregg Fonarow, MD ’87 (RES ’90, FEL ’93), Eliot Corday Chair in Cardiovascular Medicine and Science, director of the Ahmanson–UCLA Cardiomyopathy Center and co-chief of the UCLA Division of Cardiology.
“Potential Mortality Reduction with Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure,” JAMA Cardiology, June 22, 2016